炎症性肠病女性胎儿暴露于生物制剂和硫嘌呤后的妊娠与新生儿结局
2007至2019年美国多中心前瞻性观察研究纳入1490例完成妊娠的IBD孕妇,比较宫内暴露于硫嘌呤、生物制剂或两者联合与未暴露者的5种不良结局。药物暴露未增加先天畸形、自然流产、早产、低出生体重和婴儿感染率;疾病活动度较高与自然流产及婴儿感染风险相关。作者结论认为这些药物可在整个妊娠期继续使用以控制疾病活动。
要点
- IBD孕妇宫内暴露于生物制剂、硫嘌呤或联合治疗未增加先天畸形、自然流产、早产、低出生体重和婴儿感染风险。
- 疾病活动度较高与自然流产风险相关(HR 3.41,95%CI 1.51-7.69)。
- 早产与婴儿感染风险增加相关(OR 1.73,95%CI 1.19-2.51)。
核心结论
- 妊娠期暴露于生物制剂、硫嘌呤或联合治疗与出生时及生后第一年不良母婴结局增加无关。
- 作者认为IBD女性可在整个妊娠期继续使用这些药物以维持疾病控制并减少妊娠相关不良事件。
研究设计与样本
- 2007年至2019年美国多中心前瞻性观察性研究,纳入IBD孕妇。
- 1490例完成妊娠,其中1431例活产,1010例有1年婴儿结局数据。
- 暴露组:硫嘌呤(n=242)、生物制剂(n=642)、两者联合(n=227);未暴露组(n=379)。
- 主要分析比较5种结局:先天畸形、自然流产、早产、低出生体重和婴儿感染。
- 采用双变量分析及校正相关混杂因素的逻辑回归模型。
主要发现
- 药物暴露未增加先天畸形、自然流产、早产、低出生体重和生后第一年感染的发生率。
- 疾病活动度较高与自然流产风险相关(风险比3.41;95%置信区间1.51-7.69)。
- 早产与婴儿感染风险增加相关(比值比1.73;95%置信区间1.19-2.51)。
临床怎么用
- 作者认为IBD女性可在整个妊娠期继续使用生物制剂、硫嘌呤或联合治疗以维持疾病控制并减少妊娠相关不良事件。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Pregnant women with inflammatory bowel disease (IBD) may require biologic or thiopurine therapy to control disease activity. Lack of safety data has led to therapy discontinuation during pregnancy, with health repercussions to mother and child. METHODS: Between 2007 and 2019, pregnant women with IBD were enrolled in a prospective, observational, multicenter study across the United States. The primary analysis was a comparison of 5 outcomes (congenital malformations, spontaneous abortions, preterm birth, low birth weight, and infant infections) among pregnancies exposed vs unexposed in utero to biologics, thiopurines, or a combination. Bivariate analyses followed by logistic regression models adjusted for relevant confounders were used to determine the independent effects of specific drug classes on outcomes of interest. RESULTS: Among 1490 completed pregnancies, there were 1431 live births. One-year infant outcomes were available in 1010. Exposure was to thiopurines (n = 242), biologics (n = 642), or both (n = 227) vs unexposed (n = 379). Drug exposure did not increase the rate of congenital malformations, spontaneous abortions, preterm birth, low birth weight, and infections during the first year of life. Higher disease activity was associated with risk of spontaneous abortion (hazard ratio, 3.41; 95% confidence interval, 1.51-7.69) and preterm birth with increased infant infection (odds ratio, 1.73; 95% confidence interval, 1.19-2.51). CONCLUSIONS: Biologic, thiopurine, or combination therapy exposure during pregnancy was not associated with increased adverse maternal or fetal outcomes at birth or in the first year of life. Therapy with these agents can be continued throughout pregnancy in women with IBD to maintain disease control and reduce pregnancy-related adverse events. ClinicalTrials.gov, Number: NCT00904878.
引用
- Mahadevan U, Long MD, Kane SV, et al. Pregnancy and Neonatal Outcomes After Fetal Exposure to Biologics and Thiopurines Among Women With Inflammatory Bowel Disease. Gastroenterology. 2020. PMID: 33227283. doi:10.1053/j.gastro.2020.11.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。